Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Naloxone

U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

Diane Bartz  |  July 28, 2017

WASHINGTON (Reuters)—Republican and Democratic lawmakers on Thursday discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines. The focus at a hearing, held by members of the House Judiciary Committee’s antitrust subcommittee, was on the use by some brand name drug companies of a U.S….

Filed under:Drug Updates Tagged with:FDAFood and Drug Administrationgeneric drugmakersgeneric drugsgeneric pharmaceutical companiesREMSRisk Evaluation and Mitigation StrategyU.S. Food and Drug Administration

U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment

Ankur Banerjee  |  February 10, 2017

(Reuters)—U.S. Sen. Claire McCaskill (D-Mo.) on Thursday asked Kaleo Pharmaceuticals to justify the more than 550% surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag. Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately…

Filed under:Drug Updates Tagged with:costsdrug pricingDrugsnaloxoneOpioid abuseOpioids

Physicians Asked to Join AMA Efforts to Reduce Opioid Abuse

Mary Beth Nierengarten  |  October 31, 2016

In 2014, the American College of Rheumatology (ACR) was one of 25 healthcare associations invited to participate in an initiative by the American Medical Association (AMA) to reduce the public health epidemic posed by the abuse of prescription opioids.1 The AMA initiative is based on the belief that physicians are professionally obligated to participate in…

Filed under:EthicsProfessional Topics Tagged with:American Medical Association (AMA)Opioid abuseopioid use disordersPrescription drugssubstance abuse disorderstask force

Liposomal Bupivacaine Helpful in Total Knee Arthroplasty

David Douglas  |  October 19, 2016

NEW YORK (Reuters Health)—Local infiltration of liposomal bupivacaine in patients undergoing total knee arthroplasty (TKA) curbed use of opioids and antiemetics and appeared to be both beneficial and cost effective in a recent study. As Dr. Bryan Sakamoto told Reuters Health by email, the results “suggest that liposomal bupivacaine is effective as part of a…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:kneeknee arthroplastyliposomal bupivacainetotal knee replacement

Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 21, 2016

After winning the initial patent infringement lawsuit filed by Janssen, Celltrion Inc. is now shipping Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to the U.S…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:BiosimilarsCelltrion Inc.FDAFood and Drug Administrationinfliximabinfliximab-dyybOpioids

U.S. Justice Department to Push Prosecutors on Opioids

Reuters Staff  |  September 18, 2016

WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…

Filed under:AnalgesicsDrug Updates Tagged with:Department of JusticeOpioidsOverdosePain

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Centers for Disease Control and PreventionChronic painGuidelinesOpioids

2015 ACR/ARHP Annual Meeting: How Gender Differences Affect Pain

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—Men and women have different mechanisms that are at work in producing pain in rheumatic diseases—a little-studied and little-appreciated fact that is crucial to developing and using the right kinds of treatments, an expert in rheumatic disease pain said in a talk at the 2015 ACR/ARHP Annual Meeting. The lack of acknowledgment of this…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)GenderPainResearchRheumatic Diseaserheumatology

Bowing to Pressure, FDA to Reform Painkiller Approval Process

Toni Clarke  |  February 7, 2016

WASHINGTON (Reuters)—Bowing to pressure from lawmakers, Dr. Robert Califf, President Barack Obama’s nominee to lead the U.S. Food and Drug Administration (FDA), said on Thursday the agency would reform its process for approving opioid painkillers. Last month, Sen. Edward Markey (D-Ma.) placed a hold on Califf’s nomination, preventing it from being voted on by the…

Filed under:AnalgesicsDrug Updates

Drug Shortages in U.S. Emergency Departments on the Rise

Madeline Kennedy  |  January 17, 2016

(Reuters Health)—U.S. emergency rooms are increasingly running short on medications, including many that are needed for life-threatening conditions, a recent study documents. Since 2008, the number of shortages has risen by more than 400%, researchers found. Half of all emergency room shortages were for life-saving drugs, and for one in 10 there were no available…

Filed under:Drug Updates Tagged with:Drug shortageemergencyEmergency Departmenthospital

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences